title: Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma.
authors.affiliation: Cancer Research Center of Lyon, Lyon, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Perier-Muzet
authors.affiliation: Cancer Research Center of Lyon, Lyon, France.
authors.forename: Amélie
authors.initials: A
authors.lastname: Boespflug
authors.affiliation: Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Poulalhon
authors.affiliation: Cancer Research Center of Lyon, Lyon, France.
authors.forename: Julie
authors.initials: J
authors.lastname: Caramel
authors.affiliation: Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Breton
authors.affiliation: Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: Luc
authors.initials: L
authors.lastname: Thomas
authors.affiliation: Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: Stephane
authors.initials: S
authors.lastname: Dalle
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects* / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced*; D046169:Dermoscopy; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D009508:Nevus, Pigmented / Q000188:drug therapy* / Q000473:pathology*; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D001384:Azetidines; D007211:Indoles; D010880:Piperidines; D013449:Sulfonamides; D000077484:Vemurafenib; D020928:Mitogen-Activated Protein Kinases; C574276:cobimetinib